Home System concept SynerFuse â„¢ Announces First Patient Implanted in Integrated Spinal Fusion and DRG...

SynerFuse â„¢ Announces First Patient Implanted in Integrated Spinal Fusion and DRG Neuromodulation Proof of Concept Study

15
0

MINNEAPOLIS, January 13, 2022 / PRNewswire / – SynerFuse, Inc., a Minneapolismedical device company, is pleased to announce the first implementation of the company’s proof-of-concept study. The study will assess the safety and tolerability of simultaneous implantation of spinal fusion material and a dorsal root ganglion neurostimulator (DRG) in patients with chronic low back pain (cLBP). The first patient was implanted by Dr. Michel Park, MD, PhD and Dr. Rohan lall, MD, at M Health Fairview University of Minnesota Medical Center.

The SynerFuse proof of concept study involves combining spinal fusion with the implant of a neurostimulator to provide stimulation of the DRG, a key nerve structure along the spine that can be targeted by neuromodulation to treat neuropathic pain. chronic. The study will assess the safety and tolerability of the integrated therapy. Patients undergoing initial spinal fusion, among other criteria, are eligible for the study. The proof of concept study supports the recruitment of up to 20 patients.

“The implantation of the first patient in our proof-of-concept study is an important milestone for SynerFuse,” said co-founder and CEO Justin zenanko. “We are one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic low back pain.”

“Bringing this patient-focused therapy from concept to first implant is a real testament to the collaboration within our company and with our surgeons and staff partners at University of Minnesota Faculty of Medicine and M Health Fairview University of Minnesota Medical Center, ”said SynerFuse co-founder and CSO, Greg Molnar, PhD.

About Chronic Low Back Pain (cLBP)
Chronic low back pain is defined as lower back pain that persists for 12 weeks or more, even after treatment of an initial injury or an underlying cause of acute lower back pain. With 500,000 procedures performed each year, spinal fusion remains a common treatment for spinal instability, albeit with a high incidence of residual neuropathic pain. The continuum of increasingly ineffective opioid therapy, additional interventions, and adjacent-level spinal fusions leaves up to 40% of patients with back surgery failure syndrome (FBSS), a condition that results in severe back surgery. persistent and significant neuropathic pain, costing the US health care system. $ 20 billion per year and significantly affecting the quality of life of patients.

About SynerFuse
SynerFuse is a Delaware Minnesota-based company in the heart of Medical Alley and the cradle of neuromodulation and innovation in medical devices. SynerFuse believes that people with cLBP / FBSS and their providers deserve a better option than spinal fusion alone. Even when spinal fusion is successful, it can often lead to residual chronic neuropathic pain and addictive opioid use. The company is working to create a new future of non-narcotic pain management for chronic low back pain with patented therapy that integrates spinal fusion material and an active neuromodulation system. For more information about the company, please visit www.synerfuse.com.

SOURCE SynerFuse